Encompass Health Corp
No SEC Form 4 filings for $EHC in the last 30 days.
Encompass Health Corp. (EHC) reported Q2 profit of $153.9 million, or $1.54 per share. Adjusted EPS was $1.55, above Zacks’ estimate of $1.48. Revenue was $1.6 billion, above the $1.57 billion forecast. The company guided full-year EPS to $6.02-$6.25 and revenue to $6.41-$6.49 billion.
Encompass Health (NYSE:EHC) reported Q2 CY2026 revenue of $1.60 billion, up 9.6% year over year, exceeding Wall Street estimates by 1.8%, according to the company. Non-GAAP adjusted EPS was $1.55, up from $1.40 and 4.7% above consensus. The company guided full-year revenue to about $6.45 billion.
Encompass Health (NYSE: EHC) reported Q2 2026 results for the quarter ended June 30, 2026. The company said revenue rose 9.6% and Adjusted EBITDA increased 9.2%. It raised full-year guidance and increased its common stock repurchase authorization to $1 billion, after repurchasing $145.8 million year to date.
Over the past 7 days, alphai's AI scored 5 news stories mentioning EHC (Encompass Health Corp). Coverage has skewed bullish: 4 bullish, 1 neutral, and 0 bearish.
Recent EHC coverage spans earnings, financial news and sector analysis.
Beat on Q2 earnings and revenue plus a specific full-year EPS and revenue outlook can drive near-term estimate revisions and sentiment.
The article discloses a fresh Q2 beat and full-year revenue outlook near estimates, which can drive near-term momentum and re-rate expectations.
The update combines an earnings/guidance beat with a larger buyback plan, supporting near-term sentiment and potentially improving capital return expectations.
Raised revenue, EBITDA, and EPS guidance alongside a larger buyback authorization suggests improving operating momentum and capital return support.
Earnings-preview framing centers on whether EHC can meet slowing revenue growth expectations after prior revenue misses.
alphai scores every news story that mentions EHC with an AI model for sentiment and relevance, and aggregates insider trades from Encompass Health Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
Encompass Health Corp. (EHC) reported Q2 profit of $153.9 million, or $1.54 per share. Adjusted EPS was $1.55, above Zacks’ estimate of $1.48. Revenue was $1.6 billion, above the $1.57 billion forecast. The company guided full-year EPS to $6.02-$6.25 and revenue to $6.41-$6.49 billion.
2 min readEncompass Health (NYSE:EHC) reported Q2 CY2026 revenue of $1.60 billion, up 9.6% year over year, exceeding Wall Street estimates by 1.8%, according to the company. Non-GAAP adjusted EPS was $1.55, up from $1.40 and 4.7% above consensus. The company guided full-year revenue to about $6.45 billion.
5 min readEncompass Health (NYSE: EHC) reported Q2 2026 results for the quarter ended June 30, 2026. The company said revenue rose 9.6% and Adjusted EBITDA increased 9.2%. It raised full-year guidance and increased its common stock repurchase authorization to $1 billion, after repurchasing $145.8 million year to date.
4 min readEncompass Health Corp (EHC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ehcearningsrelease63026.htm EX-99.1 Document Exhibit 99.1 Media Contact August 5, 2026 Polly Manuel, 205 969-4532 polly.manuel@encompasshealth.com Investor Relations Contact Mark Miller, 205 970-5860 mark.miller@encompasshealth.com Encompass Health reports results for s
6 min readEncompass Health (NYSE: EHC) is set to report Q2 earnings Wednesday after market close. The company previously reported $1.59B revenue, up 9% YoY, and beat EPS and revenue expectations. For the upcoming quarter, analysts expect 7.7% YoY revenue growth. The article cites an average analyst price target of $140.50 versus $111.75.
2 min readArgentum’s latest operator list says Brookdale Senior Living (NYSE: BKD) remains the largest senior living operator with 47,085 units across 584 communities, down from 53,794 units in 2025. Discovery Senior Living is second with 46,074 units, up from 33,692. LCS has 30,957 units, Erickson 26,425. The report also notes ownership models and that private equity is 1.5% of units.
5 min readMizuho, via Investing.com, highlighted seven U.S. healthcare stocks for growth, citing clinical catalysts and operational updates. Price targets and ratings include EYPT $36, PCVX $163, ERAS $26, ARQT $35, LNTH $115, EHC $134, and SOLV $100. Key items include EYPT Phase 3 data in Aug 2026, PCVX Phase 3 in 4Q 2026, and LNTH PDUFA mid-Aug 2026.
4 min readEncompass Health announced a private offering of $500 million in 5.875% senior unsecured notes due 2034. The company plans to use the proceeds to redeem outstanding 2028 notes and repay a portion of its revolving credit facility, aiming to extend its debt maturity profile and re-balance its capital structure. The move is expected to enhance financial flexibility and provide clarity for bondholders.
3 min readEncompass Health (EHC) saw its stock rise by 7.5% after reporting strong first-quarter 2026 earnings and raising its full-year 2026 outlook. The company's net income reached $194.5 million, and it now expects full-year earnings between $5.89 and $6.11 per share with revenue of $6.38 billion to $6.47 billion. This positive investor reaction was also influenced by ongoing growth trends and reinforced confidence in their 2026 plan.
2 min readEncompass Health Corporation (EHC) announced its Q1 revenue reached $1.59 billion, surpassing FactSet's estimated $1.57 billion. The company also posted adjusted EPS of $1.60 per share, exceeding analyst expectations of $1.49. This financial update, released on April 30, 2026, highlights a strong start to the year for the healthcare facilities and services provider.
2 min read
